A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly

Author: Dawson L.K.   Jodrell D.I.   Bowman A.   Rye R.   Byrne B.   Bernareggi A.   Camboni G.   Smyth J.F.  

Publisher: Elsevier

ISSN: 0959-8049

Source: European Journal of Cancer, Vol.36, Iss.18, 2000-12, pp. : 2353-2359

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content